2117 related articles for article (PubMed ID: 26147946)
1. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
5. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
[TBL] [Abstract][Full Text] [Related]
7. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
8. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
Tarawneh R; D'Angelo G; Macy E; Xiong C; Carter D; Cairns NJ; Fagan AM; Head D; Mintun MA; Ladenson JH; Lee JM; Morris JC; Holtzman DM
Ann Neurol; 2011 Aug; 70(2):274-85. PubMed ID: 21823155
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
10. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
11. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
[TBL] [Abstract][Full Text] [Related]
12. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
Villeneuve S; Vogel JW; Gonneaud J; Pichet Binette A; Rosa-Neto P; Gauthier S; Bateman RJ; Fagan AM; Morris JC; Benzinger TLS; Johnson SC; Breitner JCS; Poirier J;
JAMA Neurol; 2018 May; 75(5):608-619. PubMed ID: 29482212
[TBL] [Abstract][Full Text] [Related]
13. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
Vlassenko AG; McCue L; Jasielec MS; Su Y; Gordon BA; Xiong C; Holtzman DM; Benzinger TL; Morris JC; Fagan AM
Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
[TBL] [Abstract][Full Text] [Related]
15. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C
JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028
[TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
18. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.
Tarawneh R; Lee JM; Ladenson JH; Morris JC; Holtzman DM
Neurology; 2012 Mar; 78(10):709-19. PubMed ID: 22357717
[TBL] [Abstract][Full Text] [Related]
19. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
